During the immunodiagnosis of 517 cases of acute myelogenous leukemia (AML) entered into the Medical Research Council (MRC) AMLIO trials, we have observed the CD34 precursor cell antigen more frequently in AML of M2 morphology, especially in the 84% of cases with the t(8;21) chromosomal translocation, than in any other French-AmericanBritish classification group. CD34 expression was then quantified (using QlFl and Quantum Simply Cellular beads [Flow Cytometry Standards, Research Triangle Park, NCI and CD34+ standard cells). When CD34 antibody-binding capacity (ABC) of normal bone marrow (BM) precursors and leukemic blasts was compared, it was shown that AML M2 cases with t(8;21) not only had the highest percentages of CD34+ blasts, but in >80% of CD34+ cases the individual blasts expressed higher than normal levels of CD34 antigen (>60 x I O 3 ABC per cell). In addition, in 73% of this group CD34 antigen was overexpressed in an asynchronous combination with cytoplasmic myeloperoxidase (MPO). Other signs of asynchrony included high CD34 expression with CD15 andl HE RECENT FOCUS on uniform chromosomal aberrations in acute myelogenous leukemia (AML), and the confirmation of these findings by molecular probes, has identified large groups of patients whose malignancies share common pathogenetic features and represent well-defined prognostic groups."3 Frequently, these cohorts also display characteristic morphologic features such as a parody of promyelocyte development in acute promyelocytic leukemia with t( 15; 17), myelodysplasia with micromegakaryocytes and lack of Auer rods in AML with 5q abnormality, or eosinophilia in AML with i n~1 6 .~-'
During the immunodiagnosis of 517 cases of acute myelogenous leukemia (AML) entered into the Medical Research Council (MRC) AMLIO trials, we have observed the CD34 precursor cell antigen more frequently in AML of M2 morphology, especially in the 84% of cases with the t(8;21) chromosomal translocation, than in any other French-AmericanBritish classification group. CD34 expression was then quantified (using QlFl and Quantum Simply Cellular beads [Flow Cytometry Standards, Research Triangle Park, NCI and CD34+ standard cells). When CD34 antibody-binding capacity (ABC) of normal bone marrow (BM) precursors and leukemic blasts was compared, it was shown that AML M2 cases with t(8;21) not only had the highest percentages of CD34+ blasts, but in >80% of CD34+ cases the individual blasts expressed higher than normal levels of CD34 antigen (>60 x I O 3 ABC per cell). In addition, in 73% of this group CD34 antigen was overexpressed in an asynchronous combination with cytoplasmic myeloperoxidase (MPO). Other signs of asynchrony included high CD34 expression with CD15 andl HE RECENT FOCUS on uniform chromosomal aberrations in acute myelogenous leukemia (AML), and the confirmation of these findings by molecular probes, has identified large groups of patients whose malignancies share common pathogenetic features and represent well-defined prognostic groups."3 Frequently, these cohorts also display characteristic morphologic features such as a parody of promyelocyte development in acute promyelocytic leukemia with t( 15; 17), myelodysplasia with micromegakaryocytes and lack of Auer rods in AML with 5q abnormality, or eosinophilia in AML with i n~1 6 .~-'
In another form of AML, M2 with t(8;21), the morphologic changes are so typical that the aberrant morphology has guided the identification of this subgroup at the time of its cytogenetic discovery. ' The main features of this disease are prominent Auer rods, heralding a disturbed maturation of the granulocytic lineage, and typical or CD56, as well as aberrant combinations of CD13 with terminal deoxynucleotidyl transferase (TdT) and CD19. These findings demonstrate that asynchrony is identifiable in virtually every case of AML with t(8;21), although it does not always involve the same antigens. M2 cases with t(8;21), mostly CD34+, had a 100% remission rate and 71% 5-year survival rate; other patients with CD34+ or CD34-AML showed 69% and 84% remission rates and 31% and 36% 5-year survival rates, respectively. Consequently, individual markers such as CD34 should be interpreted in relation to other features such as chromosomal changes. These simple methods, which are well suited t o quantify the expression of ligands, are a useful contribution t o diagnosis: 60% t o 65% of M2 cases with t(8;21) are rapidly identified by CD34 overexpression alone. This aberration, together with the other signs of asynchrony seen at presentation, can be used t o search for residual leukemia after therapy. 0 1996 b y The American Society of Hematology.
localized Sudan black B and myeloperoxidase (MPO) staining in the Golgi region in the absence of monocytic involvement. In this early study, the nuclear immaturity amid signs of cytoplasmic maturation was also noted7-but the techniques were not yet available for a full documentation of maturation asynchrony. However, recent immunologic methods are fully suited to perform such an analysis for three main reasons: ( l ) a range of differentiation antigens, both membrane-associated and intracellular, are available to investigate stages of myeloid differentiation-and these define the precise sequence of development in the normal myeloid lineage'""; (2) these markers can be studied with monoclonal antibodies (MAbs) labeled with various fluorochromes in three-and four-color combinations'","; and (3) expression of these antigens can be quantified as antibody-binding capacity (ABC) along the normal maturation pathway-with the clear intention of comparing these features with those seen on malignant cells."'~'' Indeed, previous phenotypic studies on AML M2 with t(8;21) have already pointed to an aberrant CD19 expression''-Is together with interleukin-5 responsiveness'' and CD56I4.I6 and CD34"-" display.
To apply these recent developments, in this study we selected cases of AML M2 with t(8;21) to analyze precursor cell-associated markers such as CD34 or terminal deoxynucleotidyl transferase (TdT) in combination with differentiation antigens including MPO, CD13, and CD15. We then compared the results with those observed in other cases of AML and in fetal bone marrow (BM). Furthermore, we quantified the expression of these molecules, since it has been demonstrated that the intensity of CD34 expression in normal BM precursor cells is variable,I7 and only CD34'"" precursors coexpress cytoplasmic MPO.I8 Such an analysis of CD34 expression, in the context of other morphologic and cytogenetic features, is of clinical relevance because several investigators have previously indicated that the expression of CD34, when investigated as an independent parameter, For personal use only. on . by guest www.bloodjournal.org From appeared to be predictive of poor clinical o u t~o m e . '~-~~ However, this finding seems to contradict the fact that AML M2 with t(8;21) is a favorable prognostic category'*3323s24 despite CD34 positivity of the blasts." -13 In this study, a total of 517 patients entered onto Medical Research Council (MRC) AMLlO therapeutic trials were studied. We describe the overexpression of CD34 antigen in AML M2 with t(8;21) and reveal the characteristic asynchrony when CD34 is studied in combination with MPO. This asynchrony also coincides with other aberrant phenotypic features, contributing to the differential diagnosis and allowing the immunologic monitoring of patients for the presence of residual disease.
PATIENTS AND METHODS
Selection ofpatients. Immunodiagnostic, cytochemical, and cytogenetic results were available on 517 BM and blood samples from patients with AML aged 17 to 55 years (mean, 47.5 y). Clinical follow-up data were available from the adult AMLlO trial of the MRC of Great Britain. The hematologic diagnosis followed the guidelines of the French-American-British classification based on morphology and cytocherni~try.~~ Routine immunophenotyping results were obtained by immunofluorescence microscopy or flow cytometry as described later. The treatment included four courses of intensive chemotherapy consisting of daunorubicin, cytarabine, and (Table 1) . After washing in phosphate-buffered saline, the stained cells were fixed in 0.5% para- Detection of cytoplasmic and nuclear antigens. During routine immunodiagnosis, detection of cytoplasmic M P 0 and nuclear TdT was performed on cytospins using anti-MP0 MAb (Dakopatts Ltd, High Wycombe, Bucks, UK) with alkaline phosphatase anti-alkaline phosphatase (Dakopatts), and rabbit anti-TdT serum with goat anti-rabbit Ig labeled with rhodamine (TRITC) as a second layer (Supertech, Bethesda, MD). M P 0 and TdT were also detected with direct IF using anti-MPO-FITC (Dakopatts) and anti-TdT-FITC (HTdT-6; Supertech) after fixing and permeabilizing the cells with Permeafix (OPF; Ortho Diagnostic Systems, Inc, Raritan, NJ). The cells (2.5 to 5 X 105/50 pL) were fixed for 30 minutes at 20°C in 800 pL OPF diluted in a 1:l ratio with distilled water," and after washing in PBS, they were incubated with 5 pL anti-MPO-FITC or anti-TdT-FITC for 30 minutes at 20°C. The cells were labeled for membrane CD34-PE with QBend-PE (kindly donated by Professor M. Greaves, LRF Leukaemia Laboratories, London, UK) before fixation and then stained for intracellular antigens (see above). Cyto- Quantifation of CD34 expression. FACScan was set on logarithmic scale. Instrument settings and channel compensations were controlled by calibrated fluorescence reference beads Quantum (Flow Cytometry Standard, Research Triangle Park, NC). Intensity of CD34 expression was measured as ABC per cell on standard cells with indirect IF using the QIFI kit (Biocytex, Marseille, France) as described previously.28 Both the first layer, CD34 MAb (BI3C5; Seralab Ltd, Crowley Down, UK), and the affinity-purified second layer, goat anti-mouse Ig (GcuMIg-FITC; Southern Biotechnology Associates, Birmingham, AL), were used at pretitrated saturated conditions. One standard was CD34+ AML blasts taken from a single patient at the start of the study (PJ-AML), frozen in small aliquots, and thawed with more than 90% viability whenever needed throughout the investigations. These PJ-AML blasts expressed 64 X IO' CD34 mean ABC per cell when tested with the QIFI test. These two reagents showed an excellent correlation on the various cases of AML (R2 = .99; not shown) and could therefore be interchangeably used in two-and three-color IF combinations.
Statistics. Life-table analyses with Kaplan-Meier curves were prepared at the MRC Clinical Trials Service Unit, Cancer Studies Unit, Oxford, UK, using the Statistical Analysis System (Cary, NC) and the Mantel-Haenschel chi-square test. The nonparametric MannWhitney ( I test was also applied.
RESULTS
Quantitation of CD34 antigen density in normal BM.
The mean percentage of CD34+ cells in the mononuclear fraction of fetal and normal BM was 6.2% (range, 1% to 20%; n = 6). There was a difference in CD34 binding capacity of small-to intermediate-size cells (mean, 26.5 X 10' ABC per cell) versus larger cells (mean, 42 X lo' ABC per cell), as determined by gating cells of differing sizes on the scatter plot and calculating their CD34 ABC values. This was confirmed by double staining with CD10 MAb: CD34+/ CD10+ cells (B-cell precursors) displayed lower CD34 ABC (mean, 29.5 X lo' ABC per cell) than CD34+/CD10-cells with larger size that include early myeloid precursors (mean, 44 X lo3 ABC per cell). Very few, if any, cells could be observed with more than 60 X 10' CD34 ABC per cell; this value can be considered the upper limit of CD34 expression on precursor cells in fetal and normal BM. Double staining for CD34 and MP0 in normal and fetal BM showed that among CD34+ cells, the MPO-majority population (R2 gate in Fig lb) expressed higher levels of CD34 (median, 25 X lo3 CD34 ABC per cell; Fig IC) than the rare MPO+ forms (R3 gate in Fig lb; median, 16 X lo' CD34 ABC per cell; Fig Id) .
Incidence of CD34 positivity in AML. When grouped by French-American-British criteria, among 5 17 cases of AML tested, 103 (19.9%) were MOM1, 152 (29.4%) M2, and 65 (12.6%) M3, and 174 (33.8%) showed signs of monocytic differentiation, including 121 cases of M4 and 53 of M5 (Fig 2) , with 21 cases (4.1%) in other minor categories (not shown). It was found that CD34 positivity, identified by more than 20% CD34' cells within the blast population, was less frequent in AML M3 and M5 (18% and 28% of cases, respectively) than in the other AML subtypes (39% to 42% of cases); nevertheless, these differences were not statistically significant (Fig 2) .
The incidence of CD34 expression was checked among M2 cases with t(8;21). In this group, higher CD34 expression was seen than in the other cases with M2 morphology without t(8;21) ( P < .001). In 32 of 38 t(8;21) cases tested (84.2%) more than 20% leukemic blasts were CD34+, with a mean of 68.5% (range, 20% to 98%). Nevertheless, six cases of M2 with t(8;21) representing 15.8% of t(8;21) cases were CD34-.
Quantitation of CD34 antigen expression in AML. Since both microscopic and flow-cytometric observations indicated that in a number of AML M2 cases CD34 staining was particularly strong, the CD34 ABC was quantified in about one third of all CD34' leukemias entered into the trial. These were morphologically characterized as seven MO, 18 M1, eight M2 without t(8;21), l1 M2 with t(8;21), and nine with monocytic differentiation (M4/5). CD34 ABC was significantly higher in AML with t(8; 2 l) than in any other group of AML (Fig 3) ; six of 11 cases displayed values more than twofold higher (300 to >400 X lo3 ABC per cell) than the highest CD34 ABC (144 X lo3 ABC per cell) found in other cases of AML without t(8;21). In nine of 11 cases (82%), CD34 ABC was higher than the upper limit of the CD34 range for normal BM (60 X 10' ABC per cell).
CD34 ABC was also higher than the mean CD34 expression seen in normal BM (30 X loq ABC) in seven of 18 (38%) M1, three of eight (37.5%) M2 without t(8;21), and three of nine (33%) AML. Nevertheless, only seven of 42 cases (16.7%) of AML without t(8;21) had higher than the maximal levels of CD34 expression seen in normal fetal BM (Fig 3) .
Aberrant features of myeloblasts in AML M2 with t(8;21).
A total of 18 cases were investigated in further detail, all of which showed t(8;21)-associated cytologic and cytochemical features' such as M2 morphology displaying varying degrees of granulocytic maturation, with Auer rods seen in all cases. There was no evidence of any monocytic component on either morphology or esterase staining or any demonstrable erythroid or megakaryocytic abnormalities. The blasts also displayed the typical nuclear indentation with a prominent Golgi region. Granulocyte maturation was abnor- mal in all cases, with asynchronously poor nuclear maturation and cytoplasmic hypogranularity from the myelocyte stage onward. Sudan black B staining revealed a typical localized positivity in the Golgi region within the blasts, and a small proportion of blasts were chloroacetate esterasepositive. The eosinophils, where present, usually showed variable granule size and amphophilic staining. When studied by flow cytometry ( Table 1 ) the blast cells had a similar pattern of FSc/SSc, with most cells locating within the myeloid blast region (54% to 91%; mean, 72.5%) and spreading toward the differentiating myeloid cell region (Fig le) . Four markers showed a relative uniformity of this patient group. The high proportions of CD34' cells were accompanied by similarly high percentages of blasts positive for class 11, CD13, and MP0 in all except one or two unusual cases with each single marker studied (Table l) tivity, confirming the lack of monocytic differentiation, was also uniform, whereas the expression of CD15 was heterogeneously positive in 39% of cases when tested with a VIMDSlike antibody reacting with the nonsialated determinant of the Lewis' antigen.' Among I8 cases of AML with t(8;2 I), 13 were studied for CD56 expression. Six of these (46%) had more than 40% CD56' myeloblasts coexpressing CD34-a leukemia-associated combination.'" A sign of asynchronous development was the expression of nuclear TdT in myeloblasts that coexpressed membrane CD13 or cytoplasmic MP0 in six of 14 cases tested (42%)-and again, these features are leukemia-associated.3' Nevertheless, the most frequent aberration in AML M2 with t(8;21) was the overexpression of CD34 antigen, which was formally quantified and found to be above the levels in Table 11 .
CD34' cells seen in normal and fetal BM in nine of I 1 cases (81%; Fig 3) . Furthermore, in eight of these samples (73%), CD34 showed an asynchronous combination with MP0 above the levels seen in normal BM'8 (Fig l) . A distinctive live gating (R5 in Figs I f and h) clearly identified large proportions of malignant blasts, indicating which parameters should primarily be used when remission samples are analyzed from the same patient. The high levels of CD34 expression in combination with another marker of granulocytic differentiation, CD15, were also recorded in seven of 18 cases analyzed (39%), although the double-stained blasts were relatively few in two cases (Table l) .
Finally, strong CD19 expression by CD34' myeloblasts was detected in three cases, whereas in other samples the CD19' peak, when studied with the RFB9 MAb used, showed weak positivity but could not be fully separated from negative control; the CD19 ABC per cell was low (not shown). Cytoplasmic CD22 and CD79a, bona fide Blineage-specific antigens, were negative in all cases, including those that were TdT-positive. Taken together, these observations demonstrate that aberrant andor asynchronous combinations are identifiable in virtually every case of AML M2 with t(8;21), although these changes are not fully uniform (Fig 4) and in 15% to 20% of AML M2 with t(8;21) do not express strong CD34 positivity (Figs 2 and 3) .
Correlation with clinical outcome. Clinical outcome for 38 patients with t(8;21) and 479 patients with other forms of AML is shown in Table 2 Table 2 ). Taken overall, the CR rate was significantly better in CD34-patients than in CD34' patients (84% v 75%, P = .008), but there was no survival difference (38% v 37% at 5 years). When the t(8;21) group was studied separately, six CD34-patients
PORWIT-MacDONALD ET AL
were still all in remission, and 32 CD34' patients had an excellent 62% 5-year survival rate (Fig 5) ; nevertheless, this CD34-versus CD34' comparison, due to the small sample size of CD34-patients with t(8;21), is uninterpretable. When the non-t(8;21) group was analyzed separately, CD34-patients had a significantly higher CR rate (84%) and marginally better survival (36%) than the CD34' group (69% CR and 3 1 % survival). However, the difference between CD34-and CD34' subgroups is relatively small compared with the greater impact of cytogenetics.
DISCUSSION
The AML M2-associated t(8;21)(q22;q22.3) results in fusion of the AMLl gene on chromosome 21 with a gene on chromosome 8 referred to as ET0.".33 These molecular findings already provide insights into the altered function of the AMLIETO protein in the processes normally regulated by AMLl gene during myeloid differentiation.3 In this report, we characterize the complexity of these changes when measured in these malignant AML blasts with quantitative immunologic techniques. In all of these cases, irregular control of cellular differentiation can be demonstrated with simple combination staining for precursor cell features such as CD34 or TdT versus signs of myeloid differentiation such as MPO, CD1 3, and CD15 display. Furthermore, many of these alterations appear to be characteristic for this particular disorder. Further extended use of the quantitative techniques used in this study on a larger cohort of patients will be required to see whether such changes occur at all in AML without t(8;21). The most obvious of these changes is the overexpression of CD34 antigen in MPO-positive malignant myeloblasts. Nevertheless, these changes are not fully uniform (Fig 4) , and 16% of AML with t(8;21) are CD34-. Thus, the complexity of the changes argues for a disturbed regulatory control rather than for mere involvement of genes that directly regulate these particular proteins.
One of the main features of our study has been the quantitation of CD34 antigen on normal and leukemic cells in combination staining with other MAbs, eg, for cytoplasmic MPO. This necessitated the use of CD34-FITC and CD34- PE reagents. If a single reagent is used in an investigation, the molecules equivalent to soluble fluorochromes (MESF units) are adequate to obtain comparative data.30 In our case, it was more appropriate to introduce standard CD34' cells that expressed known values for ABC per cell established by the QIFI test in indirect IF28,29,34 to secure the reproducibility of the performance of directly conjugated CD34 used in diagnostic staining combinations (see the methods). In this way, quantitative IF becomes a practical possibility. The same methods have already been applied to document the overexpression of CD10 antigen on 44% of cases with acute lymphoblastic leukemia.34
Expression of CD34 in AML has previously been associated with the poorly differentiated French-American-British subgroups MO and Ml,35.36 and several studies have suggested that CD34 positivity may be related to a poor clinical response in terms of CR and/or s u r v i~a l . '~.~~-~~ In this context, the observations of Lanza et al,37 who also find that the "bright" CD34 expression is associated with poor prognosis, are particularly interesting. This is because cytogenetic analysis reveals that their AML M2 group lacks cases with t(8;21) but primarily shows -5 and 5q-involvement, a known poor prognostic sign.38 Thus, our investigations, based on large numbers of patients who were uniformly treated in the AMLlO multicenter may resolve the apparent discrepancies seen in the literature that appear to be due to different proportions of patients with various chromosomal abnormalities in the individual studies. On one hand, when we excluded t(8;21) patients from the evaluation, CD34+ AML cases were less likely to obtain CR and showed slightly inferior 5-year survival as compared with the CD34-group (Fig 5) . These findings are reminiscent of the poor prognostic significance of CD34 expression, save the t(8;21) group. On the other hand, we confirm the survival advantage of patients with t(8;21) despite the obviously bright CD34 expression on most of these cases.1.23 In conclusion, these findings indicate that individual markers such as CD34 positivity should not be taken out of the context of the overall clinical and cytogenetic presentation, but should be used for patient assessment as part of the diagnosis. Our studies also confirm other observations that emphasize the relevance of chromosomal changes in interpreting the prognostic significance of lymphoid marker expression such as CD19 and CD211.39, as well as CD7,40 in the various forms of AML.
A clear example of the diagnostic advance inherent in our investigation is the use of quantitative IF for rapid diagnosis, as well as remission assessment, in t(8;21) AML. Sensitive polymerase chain reaction techniques have uniformly revealed the persistence of AML1-ET0 fusion gene in patients during remission, sometimes as long as 52 months after therapy.3,41-44 This is a clear step toward a better understanding of a multistep process in malignancy, but it questions the clinical utility of these molecular probes during the remission phase. Residual-disease assessment with immunologic methods in these diseases should now include analysis of CD341 CD56,L4,16 CD13/TdT?' CD19/CD13,'1,'2"4.39 and CD34/ MPOLs (and this study), together with a quantitative analysis of CD34 expression as delineated in this report. It will be interesting to observe whether patients with identifiable molecular disease retain or lose signs of asynchrony in myeloid development while remaining in an apparent clinical remission.
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